GO:0034348 type III interferon receptor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0034348 (type III interferon receptor activity) is a molecular function that binds type III interferons (IFN-λ) and transmits signals across the membrane.
• The receptor is a heterodimer of IFNLR1 (IL-28Rα) and IL10RB, and its limited expression restricts IFN-λ responses to epithelial cells and specific immune cells.
• IFN-λ signaling induces antiviral and immunomodulatory programs, but in gut epithelium it can also trigger pyroptosis and impair mucosal repair.
• Type III interferon receptor activity shapes thymic B cell activation and regulatory T cell generation, linking innate sensing to adaptive tolerance.
• Defective or limited receptor expression reduces antiviral efficacy, as shown for bovine viral diarrhea virus in bovine turbinate cells.
• CRISPR-based knockout, knock-in, and overexpression models are essential to dissect receptor function in disease contexts.
Description
Type III interferon receptor activity (GO:0034348) is the molecular function by which a cell-surface receptor binds type III interferons (IFN-λ) and transmits a signal across the membrane to initiate changes in cell activity. Interferon lambda is the only member of the type III interferon family identified so far, and its receptor is a heterodimer of IFNLR1 (also known as IL-28Rα) and IL10RB. This receptor activity is central to mucosal antiviral defense and immune regulation, particularly in epithelial barriers. Researchers study GO:0034348 to understand how IFN-λ responses are restricted to specific tissues, how they contribute to disease pathology such as inflammatory bowel disease and viral infections, and how they can be harnessed therapeutically. The receptor's limited expression pattern makes it an attractive target for tissue-specific modulation of immunity.
type III interferon receptor activity At A Glance
| GO ID | GO:0034348 |
|---|---|
| GO term | type III interferon receptor activity |
| Ontology | molecular_function |
| Synonym | interferon-lambda receptor activity |
| Major function | Binds type III interferons (IFN-λ) and transmits signals across the membrane to initiate cellular responses |
| Major receptor components | IFNLR1 (IL-28Rα) and IL10RB heterodimer |
| Ligand | Interferon lambda (IFN-λ), the only known type III interferon |
| Tissue expression | Predominantly epithelial cells, with limited expression in immune cells |
| Associated processes | Antiviral defense, mucosal immunity, regulation of cell death and repair |
What Is GO:0034348?
According to the Gene Ontology, type III interferon receptor activity (GO:0034348) is defined as combining with a type III interferon and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity. Interferon lambda is the only member of the type III interferon found so far. In simpler terms, it is the function of a receptor that recognizes IFN-λ outside the cell and triggers signaling inside the cell, leading to antiviral and immune responses.
Why Is type III interferon receptor activity Important in Cell Biology?
Type III interferon receptor activity is critical for understanding how the immune system defends mucosal surfaces against viral infections while maintaining tissue homeostasis. Unlike type I interferon receptors, which are broadly expressed, the type III interferon receptor is largely restricted to epithelial cells, allowing for targeted antiviral responses with reduced systemic inflammation. This receptor activity is implicated in diverse biological outcomes, from protection against viruses such as rotavirus and bovine viral diarrhea virus to modulation of adaptive immunity through thymic B cells and regulatory T cells. Dysregulation of this receptor can lead to impaired mucosal repair and inflammatory pathology, making it a key focus for therapeutic development in infectious and autoimmune diseases.
• Mediates antiviral defense in epithelial barriers, including the gut and respiratory tract.
• Restricts IFN-λ responses to specific tissues due to limited receptor expression, reducing systemic side effects.
• Plays a role in gut mucosal repair and pyroptosis, with implications for inflammatory bowel diseases.
• Links innate immune sensing to adaptive immunity by driving thymic B cell activation and regulatory T cell generation.
• Contributes to host defense against rotavirus and other enteric viruses.
• Is a potential therapeutic target for modulating mucosal immunity without broad interferon toxicity.
• Its limited expression can reduce the efficacy of IFN-λ-based antivirals in certain cell types.
• Interacts with RIG-I-like receptor signaling pathways to amplify antiviral responses.
• Relevant to autoimmune diseases where interferon signatures are prominent.
• Enables tissue-specific gene editing strategies to study receptor function in vivo.
Core Mechanisms of type III interferon receptor activity
Ligand Binding and Receptor Activation
In simple terms: The receptor grabs IFN-λ outside the cell and switches on.
Type III interferon receptor activity begins when IFN-λ binds to the extracellular domain of the IFNLR1 subunit of the heterodimeric receptor complex. This binding induces a conformational change that brings IFNLR1 and IL10RB together, activating associated Janus kinases (JAKs) and leading to phosphorylation of STAT transcription factors. The activated receptor complex thus transmits the signal across the membrane, initiating changes in gene expression.
Signal Transduction and Gene Expression
In simple terms: The signal travels to the nucleus and turns on antiviral genes.
Following receptor activation, JAK-mediated phosphorylation of STAT1 and STAT2 leads to formation of the ISGF3 complex, which translocates to the nucleus and drives transcription of interferon-stimulated genes (ISGs). These ISGs establish an antiviral state and modulate immune responses. The specific set of genes induced can vary by cell type and context, contributing to the tissue-specific effects of type III interferons.
Tissue-Specific Responses and Pyroptosis
In simple terms: In the gut, this receptor can trigger cell death and affect healing.
In gut epithelial cells, type III interferon receptor activity can induce pyroptosis, a form of inflammatory cell death, and impair mucosal repair. This dual role highlights the need to understand context-dependent outcomes of receptor signaling, as it can be protective against pathogens but also contribute to tissue damage. The limited expression of IFNLR1 in epithelial cells restricts these effects to specific tissues.
Regulation by Host and Viral Factors
In simple terms: Viruses and host proteins can tweak the receptor pathway.
Host factors such as RIG-I-like receptors and viral proteins regulate the type III interferon receptor pathway at multiple levels. For example, viral antagonism of interferon signaling can blunt receptor activity, while host sensing pathways can enhance IFN-λ production and receptor responsiveness. This interplay determines the outcome of infections and is a target for therapeutic intervention.
Key Genes Involved in GO:0034348 type III interferon receptor activity
The following genes encode the receptor subunits, signaling molecules, and regulatory factors that constitute or modulate type III interferon receptor activity.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IFNLR1 | Encodes the IFN-λ-specific subunit (IL-28Rα) of the receptor | Determines ligand specificity and tissue restriction; knockout reduces antiviral responses |
| IL10RB | Encodes the shared subunit of the receptor complex | Essential for signal transduction; mutations affect receptor function |
| JAK1 | Tyrosine kinase that phosphorylates STAT proteins upon receptor activation | Key mediator of IFN-λ signaling; knockout abolishes responses |
| TYK2 | Tyrosine kinase associated with the receptor complex | Participates in signal transduction; required for full activation |
| STAT1 | Transcription factor activated by receptor signaling | Drives ISG expression; essential for antiviral effects |
| STAT2 | Transcription factor that forms ISGF3 with STAT1 | Critical for type III interferon-induced gene expression |
| IRF9 | Component of the ISGF3 complex | Mediates transcriptional activation downstream of receptor |
| IFNL1 | Encodes IFN-λ1, a type III interferon ligand | Binds receptor to initiate signaling; used in functional studies |
| IFNL2 | Encodes IFN-λ2, a type III interferon ligand | Alternative ligand for receptor activation |
| IFNL3 | Encodes IFN-λ3, a type III interferon ligand | Associated with viral clearance and receptor binding |
| IFNL4 | Encodes IFN-λ4, a type III interferon ligand | Modulates receptor activity and antiviral responses |
| RIG-I (DDX58) | Cytosolic sensor that induces IFN-λ production | Links innate sensing to receptor ligand availability |
| MDA5 (IFIH1) | Cytosolic sensor for viral RNA | Contributes to IFN-λ induction and receptor pathway activation |
| MAVS | Mitochondrial adaptor in RIG-I-like receptor signaling | Required for IFN-λ production and subsequent receptor engagement |
| IRF3 | Transcription factor activated by RIG-I-like receptors | Induces IFN-λ gene expression |
| IRF7 | Transcription factor amplifying interferon production | Enhances ligand availability for receptor |
| NF-κB | Transcription factor involved in immune responses | Cooperates with IRFs to induce IFN-λ |
| SOCS1 | Negative regulator of cytokine signaling | Modulates receptor signaling intensity |
How Is type III interferon receptor activity Regulated?
Type III interferon receptor activity is regulated at multiple levels, including receptor expression, ligand availability, and negative feedback loops. The expression of IFNLR1 is limited to epithelial cells and certain immune cells, which restricts responsiveness to IFN-λ. Viral infection induces IFN-λ production through RIG-I-like receptor signaling, increasing ligand availability for the receptor. Negative regulators such as SOCS proteins can attenuate receptor signaling to prevent excessive inflammation. Additionally, viral proteins can antagonize receptor pathway components, providing a mechanism for immune evasion.
type III interferon receptor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IFNLR1 | Inflammatory bowel disease; impaired mucosal repair | Intestinal epithelial cell knockout and knock-in models |
| IFNL3 | Viral hepatitis and clearance | Hepatocyte overexpression and point mutation models |
| IL10RB | Very early onset inflammatory bowel disease | Knockout in epithelial cells and organoids |
| STAT1 | Mendelian susceptibility to mycobacterial disease | Knock-in of patient mutations in cell lines |
| RIG-I (DDX58) | Antiviral innate immunity defects | Knockout and overexpression in epithelial cells |
Inflammatory Bowel Disease and Mucosal Repair
Type III interferon receptor activity in gut epithelial cells can induce pyroptosis and impair mucosal repair, contributing to inflammatory bowel disease pathogenesis. This suggests that modulating receptor activity could be therapeutic in conditions characterized by impaired mucosal healing.
Viral Infections and Antiviral Defense
The receptor mediates antiviral responses against enteric viruses such as rotavirus, and its limited expression in certain cell types can reduce the efficacy of IFN-λ-based treatments. Understanding receptor activity is crucial for developing antiviral strategies that target mucosal surfaces.
Autoimmune and Inflammatory Diseases
Interferon signatures, including type III interferon pathways, are associated with autoimmune diseases such as systemic lupus erythematosus. While type I interferons are well-studied in lupus, the role of type III interferon receptor activity is an emerging area, with potential implications for targeted therapies.
Thymic Immune Regulation
Type III interferon receptor activity drives thymic B cell activation and regulatory T cell generation, linking innate interferon responses to adaptive immune tolerance. Dysregulation of this process may contribute to autoimmunity or immunodeficiency.
From type III interferon receptor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of IFNLR1 abolish IFN-λ signaling? | IFNLR1 knockout cell lines (e.g., epithelial cells) |
| How do point mutations in IFNLR1 affect ligand binding? | Point mutation knock-in via CRISPR |
| Can tagged IFNLR1 track receptor trafficking? | Knock-in of fluorescent or epitope tags |
| Does overexpression of IFN-λ enhance antiviral responses? | Overexpression of IFNL1/2/3 in cell lines |
| What is the role of IL10RB in receptor assembly? | IL10RB knockout and rescue experiments |
| How does receptor activity affect thymic B cells? | Knockout in mouse models or primary cell cultures |
How to Study the type III interferon receptor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify ISGs induced by receptor activity |
| Proteomics | Protein abundance and modifications | Quantify receptor and signaling components |
| Phosphoproteomics | Phosphorylation events | Map STAT activation downstream of receptor |
| Fluorescence microscopy | Receptor localization and trafficking | Study receptor internalization and interactions |
| Antiviral assays | Viral replication inhibition | Assess functional antiviral activity |
| CRISPR knockout screens | Genes required for receptor function | Identify novel regulators of IFN-λ signaling |
| Reporter assays | Transcriptional activation of ISGs | Measure receptor activity in high-throughput format |
Transcriptomic Analysis of IFN-λ Responses
RNA sequencing (RNA-seq) can measure global changes in gene expression following activation of type III interferon receptor activity, identifying ISGs and pathway-specific signatures. This method is useful for comparing responses in different cell types and disease models.
Proteomic and Phosphoproteomic Profiling
Mass spectrometry-based proteomics can quantify receptor components, signaling intermediates, and post-translational modifications such as STAT phosphorylation after IFN-λ stimulation. This provides a systems-level view of receptor activity.
Imaging Receptor Localization and Trafficking
Fluorescence microscopy with tagged IFNLR1 or IL10RB can visualize receptor localization, internalization, and interactions in live cells. This helps dissect the spatiotemporal dynamics of receptor activity.
Functional Antiviral Assays
Antiviral assays using viruses such as rotavirus or bovine viral diarrhea virus can measure the functional outcome of receptor activity in epithelial cells. These assays are critical for evaluating the protective or pathological effects of IFN-λ signaling.
How CRISPR Can Be Used to Study GO:0034348 type III interferon receptor activity
Knockout
CRISPR knockout of IFNLR1 or IL10RB can completely abolish type III interferon receptor activity, providing a clean background to study downstream effects and to validate specificity of IFN-λ responses. Knockout models are also useful for identifying compensatory pathways.
Point Mutation
Introducing point mutations in IFNLR1 or IL10RB via CRISPR can mimic naturally occurring variants or disrupt specific residues involved in ligand binding or JAK association, allowing structure-function analysis of receptor activity.
Knock-in
Knock-in of epitope tags, fluorescent proteins, or reporter cassettes into the IFNLR1 locus enables real-time tracking of receptor expression, localization, and signaling dynamics in physiologically relevant contexts.
Overexpression
CRISPR-mediated overexpression of IFNLR1, IL10RB, or IFN-λ ligands can amplify receptor activity, useful for studying gain-of-function effects, enhancing antiviral responses, or producing large quantities of signaling components for biochemical assays.
How EDITGENE Supports type III interferon receptor activity Research
Researchers studying type III interferon receptor activity-related genes often need to determine whether a candidate gene is causally involved in receptor function, how mutations affect signaling, and whether modulating expression can alter disease phenotypes. EDITGENE provides a comprehensive suite of CRISPR services to address these questions with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for type III interferon receptor activity research.
Frequently Asked Questions About type III interferon receptor activity
What is type III interferon receptor activity?
Type III interferon receptor activity (GO:0034348) is the molecular function of binding type III interferons (IFN-λ) and transmitting signals across the cell membrane to initiate cellular responses.
What genes are involved in type III interferon receptor activity?
Key genes include IFNLR1 (IL-28Rα) and IL10RB, which form the receptor heterodimer, as well as signaling molecules JAK1, TYK2, STAT1, STAT2, and IRF9.
Which diseases are associated with type III interferon receptor activity?
It is associated with inflammatory bowel disease, viral infections, and autoimmune conditions such as lupus, where interferon signatures are dysregulated.
How does type III interferon receptor signaling work?
IFN-λ binds IFNLR1, causing heterodimerization with IL10RB, activation of JAK kinases, phosphorylation of STAT proteins, and induction of interferon-stimulated genes.
What is the difference between type I and type III interferon receptors?
Type III interferon receptors are largely restricted to epithelial cells, whereas type I interferon receptors are broadly expressed, leading to different tissue-specific effects.
Can type III interferon receptor activity be targeted therapeutically?
Yes, its tissue-specific expression makes it an attractive target for modulating mucosal immunity with potentially fewer systemic side effects.
What cell types express the type III interferon receptor?
It is predominantly expressed on epithelial cells, with limited expression in certain immune cells such as thymic B cells.
How is type III interferon receptor activity regulated?
It is regulated by receptor expression levels, ligand availability, and negative feedback via SOCS proteins, as well as viral antagonism.
What experimental models are used to study type III interferon receptor activity?
Common models include CRISPR knockout and knock-in cell lines, overexpression systems, and primary epithelial cell cultures.
Why is type III interferon receptor activity important for mucosal immunity?
It provides a localized antiviral defense at mucosal surfaces and helps maintain barrier integrity, but can also contribute to inflammation and tissue damage if dysregulated.
Conclusion
Type III interferon receptor activity (GO:0034348) is a specialized molecular function that enables tissue-specific responses to IFN-λ, playing critical roles in antiviral defense, mucosal immunity, and immune regulation. Its unique expression pattern and dual role in protection and pathology make it a compelling target for therapeutic intervention. Continued research using advanced CRISPR models and multi-omics approaches will further elucidate its mechanisms and disease relevance.
References
- 1. Jena KK et al.. 2024. Type III interferons induce pyroptosis in gut epithelial cells and impair mucosal repair.. Cell 187(26):7533-7550.e23 PMID: 39500322
- 2. Baker T et al.. 2024. Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials.. Ann Rheum Dis 83(8):1018-1027 PMID: 38569851
- 3. Dassanayake RP et al.. 2024. Antiviral activity of bovine type III interferon against bovine viral diarrhea virus is greatly reduced in bovine turbinate cells due to limited expression of IFN lambda receptor 1 (IL-28Rα).. Front Immunol 15:1441908 PMID: 39224597
- 4. Martinez RJ et al.. 2023. Type III interferon drives thymic B cell activation and regulatory T cell generation.. Proc Natl Acad Sci U S A 120(9):e2220120120 PMID: 36802427
- 5. Hou G et al.. 2025. Innate immune sensing of rotavirus by intestinal epithelial cells leads to diarrhea.. Cell Host Microbe 33(3):408-419.e8 PMID: 40037352
- 6. Iwamoto T et al.. 2022. High Systemic Type I Interferon Activity Is Associated With Active Class III/IV Lupus Nephritis.. J Rheumatol 49(4):388-397 PMID: 34782453
- 7. Kotenko SV. 2011. IFN-λs.. Curr Opin Immunol 23(5):583-90 PMID: 21840693
- 8. Onomoto K et al.. 2021. Regulation of RIG-I-like receptor-mediated signaling: interaction between host and viral factors.. Cell Mol Immunol 18(3):539-555 PMID: 33462384
